Macular Edema and Macular Degeneration Global Market Report 2024

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period can be attributed to several factors, including an aging population, the prevalence of diabetes, increased awareness and early diagnosis of eye conditions, global initiatives focusing on eye health, innovations in pharmaceuticals related to eye care, and the active role of patient advocacy and support. These factors collectively contributed to the growth of treatments and interventions related to eye health during the specified historical timeframe.

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $12.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of personalized medicine approaches, increasing awareness in emerging markets, a focus on combination therapies, integration with teleophthalmology services, and the global aging demographics. Major trends expected in the forecast period encompass advancements in sustained-release drug delivery, the integration of gene therapies, the development of novel imaging technologies, personalized treatment approaches based on biomarkers, the use of teleophthalmology for remote monitoring, and advancements in artificial intelligence for diagnostics in the field of eye health.

The growing population of individuals with diabetes is anticipated to drive the expansion of the macular edema and macular degeneration market in the future. Diabetes, a chronic medical condition characterized by elevated glucose levels in the blood, can lead to damage to the blood vessels in the eyes, resulting in conditions such as macular edema and macular degeneration. For example, in April 2023, The British Diabetic Association, a UK-based diabetes charity, reported a record-high number of people living with diabetes, exceeding 5 million. Of this, 4.3 million people were diagnosed with diabetes, and an estimated 850,000 people were living with the condition without a diagnosis. Additionally, over 2.4 million people in the UK were deemed at high risk of developing type 2 diabetes, with registration numbers for 2021-22 increasing by 148,951 from the previous year. Hence, the rising diabetes population is identified as a key factor propelling the growth of the macular edema and macular degeneration market.

The increasing prevalence of eye disorders is also expected to contribute to the growth of the macular edema and macular degeneration market. Eye disorders encompass a diverse range of conditions affecting the visual system, leading to vision impairment or other symptoms. Conditions such as wet age-related macular degeneration (AMD) can result in abnormal blood vessel growth and leakage, directly contributing to fluid buildup in the macula. For instance, in September 2023, National Eye Health Week, a UK-based government website, reported that late-stage age-related macular degeneration (AMD), the primary cause of blindness in the UK, is projected to increase by 25% by 2032. Additionally, early-stage AMD (drusen) is expected to increase by 16%, cataracts by 25%, and glaucoma by 17% by 2032. This underscores the significance of the increasing prevalence of eye disorders in driving the growth of the macular edema and macular degeneration market.

The high cost associated with the treatment of macular edema is anticipated to pose a challenge to the growth of the macular edema and macular degeneration market in the future. The elevated expenses related to treatment can impede access to effective therapies for individuals with macular edema, potentially leading to delayed or inadequate treatment and an increased risk of vision loss. For instance, as of March 2023, the BrightFocus Foundation, a US-based nonprofit organization, reported that the combined direct healthcare expenses linked to age-related macular degeneration-related visual impairment in the United States, Canada, and Cuba (WHO subregion AMR-A) amount to approximately US$98 billion. This highlights the significant financial burden associated with addressing macular edema and macular degeneration, hindering the market's growth.

Leading companies operating in the macular edema and macular degeneration market are directing their efforts towards developing innovative products, such as Vabysmo (faricimab-svoa), to enhance their market position. Vabysmo (faricimab-svoa) is a medication designed for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., a US-based biotechnology corporation, received approval from the Food and Drug Administration for Vabysmo (faricimab-svoa). As a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), it represents the first bispecific monoclonal antibody for both disorders. The approval of Vabysmo marked a significant milestone for Genentech and Roche, positioning it as a potential blockbuster medication for the treatment of nAMD and DME.

In October 2021, Curacle Co., a South Korea-based biopharmaceutical company, entered into a partnership with Théa Open Innovation (TOI) to develop Curacle's CU06-RE drug. This collaboration involved a $6 million initial payment to Curacle, along with an additional $157.5 million earmarked for the development, regulatory processes, and sales of CU06-RE. Both companies aim to commercialize CU06-RE, an orally administered drug designed to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Théa Open Innovation (TOI) is the French-based sister company of Laboratoires Théa, focusing on identifying, evaluating, and investing in innovative products within the field of eye care.

Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmics Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited.

North America was the largest region in the macular edema and macular degeneration market in 2023. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular edema and macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Macular edema and macular degeneration are distinct eye conditions that can impact vision. Macular edema involves swelling in the retina's part at the back of the eye, leading to blurry vision. On the other hand, macular degeneration is a condition affecting the macula, which is responsible for central vision in the retina at the back of the eye. Both conditions can be triggered by various factors, including diabetic retinopathy, retinal vein occlusion, inflammation, as well as age, genetics, smoking, high blood pressure, and obesity.

The primary types of treatment for macular edema and macular degeneration include drug therapy and laser treatment. Drug therapy entails the use of pharmaceutical drugs or medications to address, manage, or alleviate medical conditions, diseases, or symptoms related to these eye conditions. It finds applications in treating macular edema, diabetic macular edema (DME), cystoid macular edema (CME), macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration. These treatments are administered by hospitals, clinics, and other end-users.

The macular edema and macular degeneration market research report is one of a series of new reports that provides macular edema and macular degeneration market statistics, including macular edema and macular degeneration industry global market size, regional shares, competitors with macular edema and macular degeneration market share, detailed macular edema and macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the macular edema and macular degeneration industry. This macular edema and macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macular edema and macular degeneration market consists of revenues earned by entities by providing services such as ophthalmic care, ophthalmologic evaluation, imaging and diagnostics, laser therapy, photodynamic therapy, and rehabilitation and low vision services. The market value includes the value of related goods sold by the service provider or included within the service offering. The macular edema and macular degeneration market also includes sales of surgical interventions, low vision aids, dietary supplements, retinal implants, and subretinal injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.